Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain)
A fully government-funded human papillomavirus (HPV) vaccination program started in 2007 in Spain (only 11–14-year-old girls). The first of those vaccinated cohorts, with the quadrivalent vaccine (Gardasil), turned 25 years old in 2018, the age at which cervical cancer screening begins in Spain. The...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/3/387 |
| _version_ | 1797441219301736448 |
|---|---|
| author | Juan J. Hernandez-Aguado Damián Ángel Sánchez Torres Esther Martínez Lamela Gema Aguión Gálvez Eva Sanz Espinosa Almudena Pérez Quintanilla Daniela A. Martínez-Carrillo Mar Ramírez Mena Pluvio J. Coronado Martín Ignacio Zapardiel Jesús de la Fuente-Valero |
| author_facet | Juan J. Hernandez-Aguado Damián Ángel Sánchez Torres Esther Martínez Lamela Gema Aguión Gálvez Eva Sanz Espinosa Almudena Pérez Quintanilla Daniela A. Martínez-Carrillo Mar Ramírez Mena Pluvio J. Coronado Martín Ignacio Zapardiel Jesús de la Fuente-Valero |
| author_sort | Juan J. Hernandez-Aguado |
| collection | DOAJ |
| description | A fully government-funded human papillomavirus (HPV) vaccination program started in 2007 in Spain (only 11–14-year-old girls). The first of those vaccinated cohorts, with the quadrivalent vaccine (Gardasil), turned 25 years old in 2018, the age at which cervical cancer screening begins in Spain. The current study could provide the first evidence about the effectiveness of the quadrivalent vaccine against HPV in Spain and the influence of age of vaccination. The present ambispective cohort study, which was conducted on 790 women aged 25 and 26 years old, compares the rate of HPV prevalence and cytologic anomaly according to the vaccination status. The overall infection rate was 40.09% (vaccinated group) vs. 40.6% (non-vaccinated group). There was a significant reduction in the prevalence of HPV 6 (0% vs. 1.3%) and 16 (2.4% vs. 6.1%), and in the prevalence of cytological abnormalities linked to HPV16: Atypical Squamous Cells of Undetermined Significance (ASCUS) (2.04% vs. 14%), Low-grade Squamous Intraepithelial Lesions (LSIL) (2.94% vs. 18.7%) and High-grade Squamous Intraepithelial Lesion (HSIL) (0% vs. 40%), in the vaccinated group vs. the non-vaccinated group. Only one case of HPV11 and two cases of HPV18 were detected. The vaccine effectively reduces the prevalence of vaccine genotypes and cytological anomalies linked to these genotypes. |
| first_indexed | 2024-03-09T12:19:52Z |
| format | Article |
| id | doaj.art-73e375915ad148d0be9425e02f48686b |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T12:19:52Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-73e375915ad148d0be9425e02f48686b2023-11-30T22:42:14ZengMDPI AGVaccines2076-393X2022-03-0110338710.3390/vaccines10030387Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain)Juan J. Hernandez-Aguado0Damián Ángel Sánchez Torres1Esther Martínez Lamela2Gema Aguión Gálvez3Eva Sanz Espinosa4Almudena Pérez Quintanilla5Daniela A. Martínez-Carrillo6Mar Ramírez Mena7Pluvio J. Coronado Martín8Ignacio Zapardiel9Jesús de la Fuente-Valero10Gynecology Department, Infanta Leonor University Hospital, 28031 Madrid, SpainGynecology Department, Infanta Leonor University Hospital, 28031 Madrid, SpainGynecology Department, Infanta Leonor University Hospital, 28031 Madrid, SpainGynecology Department, Infanta Leonor University Hospital, 28031 Madrid, SpainGynecology Department, Infanta Leonor University Hospital, 28031 Madrid, SpainGynecology Department, Infanta Leonor University Hospital, 28031 Madrid, SpainGynecology Department, Infanta Leonor University Hospital, 28031 Madrid, SpainGynecology Oncology Unit, Institute of Women’s Health, San Carlos Clinical Hospital (IdISSC), Complutense University, 28040 Madrid, SpainGynecology Oncology Unit, Institute of Women’s Health, San Carlos Clinical Hospital (IdISSC), Complutense University, 28040 Madrid, SpainGynecologic Oncology Unit, La Paz University Hospital-IdiPAZ, 28046 Madrid, SpainGynecology Department, Infanta Leonor University Hospital, 28031 Madrid, SpainA fully government-funded human papillomavirus (HPV) vaccination program started in 2007 in Spain (only 11–14-year-old girls). The first of those vaccinated cohorts, with the quadrivalent vaccine (Gardasil), turned 25 years old in 2018, the age at which cervical cancer screening begins in Spain. The current study could provide the first evidence about the effectiveness of the quadrivalent vaccine against HPV in Spain and the influence of age of vaccination. The present ambispective cohort study, which was conducted on 790 women aged 25 and 26 years old, compares the rate of HPV prevalence and cytologic anomaly according to the vaccination status. The overall infection rate was 40.09% (vaccinated group) vs. 40.6% (non-vaccinated group). There was a significant reduction in the prevalence of HPV 6 (0% vs. 1.3%) and 16 (2.4% vs. 6.1%), and in the prevalence of cytological abnormalities linked to HPV16: Atypical Squamous Cells of Undetermined Significance (ASCUS) (2.04% vs. 14%), Low-grade Squamous Intraepithelial Lesions (LSIL) (2.94% vs. 18.7%) and High-grade Squamous Intraepithelial Lesion (HSIL) (0% vs. 40%), in the vaccinated group vs. the non-vaccinated group. Only one case of HPV11 and two cases of HPV18 were detected. The vaccine effectively reduces the prevalence of vaccine genotypes and cytological anomalies linked to these genotypes.https://www.mdpi.com/2076-393X/10/3/387HPVvaccinequadrivalent vaccine |
| spellingShingle | Juan J. Hernandez-Aguado Damián Ángel Sánchez Torres Esther Martínez Lamela Gema Aguión Gálvez Eva Sanz Espinosa Almudena Pérez Quintanilla Daniela A. Martínez-Carrillo Mar Ramírez Mena Pluvio J. Coronado Martín Ignacio Zapardiel Jesús de la Fuente-Valero Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain) Vaccines HPV vaccine quadrivalent vaccine |
| title | Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain) |
| title_full | Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain) |
| title_fullStr | Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain) |
| title_full_unstemmed | Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain) |
| title_short | Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain) |
| title_sort | quadrivalent human papillomavirus vaccine effectiveness after 12 years in madrid spain |
| topic | HPV vaccine quadrivalent vaccine |
| url | https://www.mdpi.com/2076-393X/10/3/387 |
| work_keys_str_mv | AT juanjhernandezaguado quadrivalenthumanpapillomavirusvaccineeffectivenessafter12yearsinmadridspain AT damianangelsancheztorres quadrivalenthumanpapillomavirusvaccineeffectivenessafter12yearsinmadridspain AT esthermartinezlamela quadrivalenthumanpapillomavirusvaccineeffectivenessafter12yearsinmadridspain AT gemaaguiongalvez quadrivalenthumanpapillomavirusvaccineeffectivenessafter12yearsinmadridspain AT evasanzespinosa quadrivalenthumanpapillomavirusvaccineeffectivenessafter12yearsinmadridspain AT almudenaperezquintanilla quadrivalenthumanpapillomavirusvaccineeffectivenessafter12yearsinmadridspain AT danielaamartinezcarrillo quadrivalenthumanpapillomavirusvaccineeffectivenessafter12yearsinmadridspain AT marramirezmena quadrivalenthumanpapillomavirusvaccineeffectivenessafter12yearsinmadridspain AT pluviojcoronadomartin quadrivalenthumanpapillomavirusvaccineeffectivenessafter12yearsinmadridspain AT ignaciozapardiel quadrivalenthumanpapillomavirusvaccineeffectivenessafter12yearsinmadridspain AT jesusdelafuentevalero quadrivalenthumanpapillomavirusvaccineeffectivenessafter12yearsinmadridspain |